261 related articles for article (PubMed ID: 23009753)
21. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model.
Di Monte DA; McCormack A; Petzinger G; Janson AM; Quik M; Langston WJ
Mov Disord; 2000 May; 15(3):459-66. PubMed ID: 10830409
[TBL] [Abstract][Full Text] [Related]
22. Role for α6 nicotinic receptors in l-dopa-induced dyskinesias in parkinsonian mice.
Quik M; Park KM; Hrachova M; Mallela A; Huang LZ; McIntosh JM; Grady SR
Neuropharmacology; 2012 Sep; 63(3):450-9. PubMed ID: 22579614
[TBL] [Abstract][Full Text] [Related]
23. Influence of corticostriatal δ-opioid receptors on abnormal involuntary movements induced by L-DOPA in hemiparkinsonian rats.
Billet F; Costentin J; Dourmap N
Exp Neurol; 2012 Aug; 236(2):339-50. PubMed ID: 22575599
[TBL] [Abstract][Full Text] [Related]
24. AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys.
Di Paolo T; Grégoire L; Feuerbach D; Elbast W; Weiss M; Gomez-Mancilla B
Parkinsonism Relat Disord; 2014 Nov; 20(11):1119-23. PubMed ID: 25172125
[TBL] [Abstract][Full Text] [Related]
25. Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys.
Morissette M; Samadi P; Hadj Tahar A; Bélanger N; Di Paolo T
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Apr; 34(3):446-54. PubMed ID: 20026151
[TBL] [Abstract][Full Text] [Related]
26. Brain α7 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients.
Morissette M; Morin N; Grégoire L; Rajput A; Rajput AH; Di Paolo T
Biochem Pharmacol; 2016 Jun; 109():62-69. PubMed ID: 27038656
[TBL] [Abstract][Full Text] [Related]
27. α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage.
Zhang D; McGregor M; Bordia T; Perez XA; McIntosh JM; Decker MW; Quik M
Mov Disord; 2015 Dec; 30(14):1901-1911. PubMed ID: 26573698
[TBL] [Abstract][Full Text] [Related]
28. Focal striatal dopamine may potentiate dyskinesias in parkinsonian monkeys.
Bankiewicz KS; Daadi M; Pivirotto P; Bringas J; Sanftner L; Cunningham J; Forsayeth JR; Eberling JL
Exp Neurol; 2006 Feb; 197(2):363-72. PubMed ID: 16337943
[TBL] [Abstract][Full Text] [Related]
29. Decrease in alpha3*/alpha6* nicotinic receptors but not nicotine-evoked dopamine release in monkey brain after nigrostriatal damage.
McCallum SE; Parameswaran N; Bordia T; McIntosh JM; Grady SR; Quik M
Mol Pharmacol; 2005 Sep; 68(3):737-46. PubMed ID: 15933214
[TBL] [Abstract][Full Text] [Related]
30. Multiple CNS nicotinic receptors mediate L-dopa-induced dyskinesias: studies with parkinsonian nicotinic receptor knockout mice.
Quik M; Campos C; Grady SR
Biochem Pharmacol; 2013 Oct; 86(8):1153-62. PubMed ID: 23831952
[TBL] [Abstract][Full Text] [Related]
31. Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates.
Quik M; Chen L; Parameswaran N; Xie X; Langston JW; McCallum SE
J Neurosci; 2006 Apr; 26(17):4681-9. PubMed ID: 16641249
[TBL] [Abstract][Full Text] [Related]
32. Role for the nicotinic cholinergic system in movement disorders; therapeutic implications.
Quik M; Zhang D; Perez XA; Bordia T
Pharmacol Ther; 2014 Oct; 144(1):50-9. PubMed ID: 24836728
[TBL] [Abstract][Full Text] [Related]
33. Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys.
Morin N; Morissette M; Grégoire L; Di Paolo T
Prog Neuropsychopharmacol Biol Psychiatry; 2015 Jan; 56():27-38. PubMed ID: 25046277
[TBL] [Abstract][Full Text] [Related]
34. L-DOPA treatment modulates nicotinic receptors in monkey striatum.
Quik M; Bordia T; Okihara M; Fan H; Marks MJ; McIntosh JM; Whiteaker P
Mol Pharmacol; 2003 Sep; 64(3):619-28. PubMed ID: 12920198
[TBL] [Abstract][Full Text] [Related]
35. Chronic H
Avila-Luna A; Gálvez-Rosas A; Aguirre-Pérez A; Hidalgo-Bravo A; Alfaro-Rodriguez A; Ríos C; Arias-Montaño JA; Bueno-Nava A
Psychopharmacology (Berl); 2023 Jun; 240(6):1221-1234. PubMed ID: 37086286
[TBL] [Abstract][Full Text] [Related]
36. Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates.
Quik M; Parameswaran N; McCallum SE; Bordia T; Bao S; McCormack A; Kim A; Tyndale RF; Langston JW; Di Monte DA
J Neurochem; 2006 Sep; 98(6):1866-75. PubMed ID: 16882311
[TBL] [Abstract][Full Text] [Related]
37. MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates.
Morin N; Grégoire L; Morissette M; Desrayaud S; Gomez-Mancilla B; Gasparini F; Di Paolo T
Neuropharmacology; 2013 Mar; 66():355-64. PubMed ID: 22884464
[TBL] [Abstract][Full Text] [Related]
38. Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia.
Ravenscroft P; Chalon S; Brotchie JM; Crossman AR
Exp Neurol; 2004 Jan; 185(1):36-46. PubMed ID: 14697317
[TBL] [Abstract][Full Text] [Related]
39. Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias.
Riahi G; Morissette M; Parent M; Di Paolo T
Eur J Neurosci; 2011 May; 33(10):1823-31. PubMed ID: 21501255
[TBL] [Abstract][Full Text] [Related]
40. Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.
Jourdain VA; Morin N; Grégoire L; Morissette M; Di Paolo T
J Neurosurg; 2015 Dec; 123(6):1383-93. PubMed ID: 25932606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
